| Features: Statin |
Atorvastatin is a statin, i.e., an inhibitor of HMG-CoA reductase, the rate-limiting enzyme of the mevalonate pathway. Clinically it is prescribed to lower LDL cholesterol and cardiovascular risk.Across preclinical and observational contexts, atorvastatin tends to: -DOWNREGULATE proliferative and survival signaling (via impaired prenylation) -REDUCE inflammatory signaling (NF-κB–linked effects) -MODULATE immune and stromal interactions -SENSITIZE some tumors to chemotherapy or radiation (context-dependent)-Epidemiologic studies suggest statin use is associated with reduced incidence or improved outcomes in some cancers (e.g., colorectal, prostate, breast). |
| 4978- | ATV, | Rad, | Atorvastatin Sensitizes Breast and Lung Cancer Cells to Ionizing Radiation |
| - | in-vitro, | BC, | A549 |
| 4979- | ATV, | Rad, | Short‐Term Statin Treatment Reduces, and Long‐Term Statin Treatment Abolishes, Chronic Vascular Injury by Radiation Therapy |
| - | in-vivo, | Nor, | NA |
| 4980- | ATV, | A review of effects of atorvastatin in cancer therapy |
| - | Review, | Var, | NA |
| 4981- | ATV, | Crosstalk between Statins and Cancer Prevention and Therapy: An Update |
| 4982- | ATV, | Inhibiting the mevalonate pathway with atorvastatin alters gut microbiota and has potential as an anti-cancer treatment for ovarian cancer |
| - | in-vivo, | Ovarian, | NA |
| 4985- | ATV, | Dipy, | Repurposing of the Cardiovascular Drug Statin for the Treatment of Cancers: Efficacy of Statin-Dipyridamole Combination Treatment in Melanoma Cell Lines |
| - | in-vivo, | Melanoma, | SK-MEL-28 | - | in-vitro, | BC, | MDA-MB-435 |
| 4986- | ATV, | Dipy, | The combination of statins and dipyridamole is effective preclinically in AML, MM, and breast cancer |
| - | Review, | Var, | NA |
| 4988- | ATV, | Dipy, | Repurposing of the Cardiovascular Drug Statin for the Treatment of Cancers: Efficacy of Statin–Dipyridamole Combination Treatment in Melanoma Cell Lines |
| - | in-vivo, | Melanoma, | NA |
| 4983- | Dipy, | ATV, | Targeting tumor cell metabolism via the mevalonate pathway: Two hits are better than one |
| - | Review, | Var, | NA |
| 4984- | Dipy, | ATV, | Immediate Utility of Two Approved Agents to Target Both the Metabolic Mevalonate Pathway and Its Restorative Feedback Loop |
| - | in-vitro, | AML, | NA |
| 4987- | Dipy, | ATV, | Enhanced cardioprotection against ischemia-reperfusion injury with a dipyridamole and low-dose atorvastatin combination |
| - | in-vivo, | Nor, | NA |
| 1802- | NarG, | ATV, | Bioenhancing effects of naringin on atorvastatin |
| - | in-vivo, | Nor, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:2 Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid